UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 183

Sortiert nach

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer

Annals of oncology, 2022-02, Vol.33 (2), p.169-180

2022

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials

Annals of oncology, 2014-01, Vol.25 (1), p.149-154

2014

Link zum Volltext

Verfügbarkeit prüfen

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

Annals of oncology, 2012-06, Vol.23 (6), p.1549-1555

2012

Link zum Volltext

Verfügbarkeit prüfen

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC

British journal of cancer, 2014-04, Vol.110 (8), p.1917-1922

2014

Link zum Volltext

Verfügbarkeit prüfen

A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer

Annals of oncology, 2020-02, Vol.31 (2), p.257-265

2020

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma

Annals of oncology, 2017-11, Vol.28 (11), p.2754-2760

2017

Link zum Volltext

Verfügbarkeit prüfen

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)

Annals of oncology, 2018-02, Vol.29 (2), p.361-369

2018

Link zum Volltext

Verfügbarkeit prüfen

Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel

Prostate cancer and prostatic diseases, 2015-06, Vol.18 (2), p.122-127

2015

Link zum Volltext

Verfügbarkeit prüfen

First-line (1L) or second-line (2L) avelumab monotherapy in patients (pts) with advanced renal cell carcinoma (aRCC) enrolled in the phase Ib JAVELIN solid tumor trial

Annals of oncology, 2018-10, Vol.29, p.viii310-viii311

2018

Link zum Volltext

Verfügbarkeit prüfen

Randomized trial of androgen deprivation therapy (ADT) + enzalutamide (Arm A) versus ADT + bicalutamide (Arm B) in metastatic hormone sensitive prostate cancer (mHSPC)

Annals of oncology, 2018-10, Vol.29, p.viii276-viii276

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase Ib study (COSMIC-021) of cabozantinib in combination with atezolizumab: Results of the dose escalation stage in patients (pts) with treatment-naïve advanced renal cell carcinoma (RCC)

Annals of oncology, 2018-10, Vol.29, p.viii308-viii308

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers

Annals of oncology, 2010-10, Vol.21 (10), p.1999-2004

2010

Link zum Volltext

Verfügbarkeit prüfen

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)

Annals of oncology, 2019-11, Vol.30 (11), p.1841-1841

2019

Link zum Volltext

Verfügbarkeit prüfen

Clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin inhibitors (mTORI) after immuno-oncology (IO) checkpoint inhibitors

Annals of oncology, 2018-10, Vol.29, p.viii315-viii315

2018

Link zum Volltext

Verfügbarkeit prüfen

Racial disparity in incidence patterns and outcome of kidney cancer

Urology (Ridgewood, N.J.), 2003-12, Vol.62 (6), p.1012-1017

2003

Link zum Volltext

Verfügbarkeit prüfen

Combination Paclitaxel, Carboplatin, and Gemcitabine Is an Active Treatment for Advanced Urothelial Cancer

Journal of clinical oncology, 2001-05, Vol.19 (9), p.2527-2533

2001

Link zum Volltext

Verfügbarkeit prüfen

A first-in-human phase I study to evaluate the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors

European journal of cancer (1990), 2016-12, Vol.69, p.S11-S11

2016

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide

ESMO open, 2021-04, Vol.6 (2), p.100082-100082, Article 100082

2021

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

Journal of clinical oncology, 2020-02, Vol.38 (5), p.395-405

2020

Link zum Volltext

Verfügbarkeit prüfen

2619 Patterns and potential benefit of adjuvant chemotherapy for residual muscle invasive disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC)

European journal of cancer (1990), 2015-09, Vol.51, p.S518-S518

2015

Link zum Volltext

Verfügbarkeit prüfen

Development of cabozantinib for the treatment of prostate cancer [Corrigendum]

Core evidence, 2014-05, Vol.9, p.69-69

Vaishampayan, Ulka

2014

Link zum Volltext

Verfügbarkeit prüfen

A PHASE 1 STUDY OF BET INHIBITION USING RG6146 IN RELAPSED/REFRACTORY (R/R) MYC‐EXPRESSING DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)

Hematological oncology, 2017-06, Vol.35 (S2), p.263-265

2017

Link zum Volltext

Verfügbarkeit prüfen

A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies

International journal of radiation oncology, biology, physics, 2002-07, Vol.53 (3), p.675-679

2002

Link zum Volltext

Verfügbarkeit prüfen

A0477 - Patients experience with recurrence of renal cell carcinoma

European urology, 2023-02, Vol.83, p.S681-S681

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 183

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(168)
Mit Volltextzugriff
(180)

Publikationsform

Sprache

Englisch
(183)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(67)
Science & Technology
(67)
Humans
(60)
Male
(52)
Middle Aged
(43)
Oncology
(42)
Aged
(41)
Biological And Medical Sciences
(34)
Medical Sciences
(33)
Female
(29)
Adult
(26)
Tumors
(21)
Treatment Outcome
(20)
Chemotherapy
(19)
Aged, 80 And Over
(16)
Antineoplastic Agents
(16)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(16)
Nephrology. Urinary Tract Diseases
(16)
Tumors Of The Urinary System
(16)
Pharmacology. Drug Treatments
(15)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer

Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC

A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)

Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel

First-line (1L) or second-line (2L) avelumab monotherapy in patients (pts) with advanced renal cell carcinoma (aRCC) enrolled in the phase Ib JAVELIN solid tumor trial

Randomized trial of androgen deprivation therapy (ADT) + enzalutamide (Arm A) versus ADT + bicalutamide (Arm B) in metastatic hormone sensitive prostate cancer (mHSPC)

Phase Ib study (COSMIC-021) of cabozantinib in combination with atezolizumab: Results of the dose escalation stage in patients (pts) with treatment-naïve advanced renal cell carcinoma (RCC)

A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)

Clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin inhibitors (mTORI) after immuno-oncology (IO) checkpoint inhibitors

Racial disparity in incidence patterns and outcome of kidney cancer

Combination Paclitaxel, Carboplatin, and Gemcitabine Is an Active Treatment for Advanced Urothelial Cancer

A first-in-human phase I study to evaluate the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors

A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

2619 Patterns and potential benefit of adjuvant chemotherapy for residual muscle invasive disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC)

Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer

Development of cabozantinib for the treatment of prostate cancer [Corrigendum]

A PHASE 1 STUDY OF BET INHIBITION USING RG6146 IN RELAPSED/REFRACTORY (R/R) MYC‐EXPRESSING DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)

A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies

A0477 - Patients experience with recurrence of renal cell carcinoma

Suchergebnisse filtern